This file has been accepted for review by the European Medicines Agency (EMEA). Clinical trials, involving more than 7,000 adult or elderly participants, evaluated the safety and ability to generate an immune response of this novel intradermal (ID) seasonal influenza vaccine. The ID vaccine generated a superior level of seroprotective immune response against all tested influenza strains, compared with standard intramuscular influenza vaccination, in study participants.